Astria Therapeutics (NASDAQ:ATXS) Upgraded at Cantor Fitzgerald

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) was upgraded by research analysts at Cantor Fitzgerald to a "strong-buy" rating in a note issued to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Astria Therapeutics' FY2025 earnings at ($1.98) EPS.

Other equities research analysts have also recently issued reports about the company. Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a research note on Friday, January 31st. JMP Securities initiated coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They set an "outperform" rating and a $26.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Finally, Wedbush reaffirmed an "outperform" rating and set a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Five research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $30.00.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock traded up $0.20 during trading hours on Tuesday, reaching $5.36. The company's stock had a trading volume of 408,704 shares, compared to its average volume of 364,057. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.92. The company's 50 day simple moving average is $5.40 and its 200 day simple moving average is $7.90. The stock has a market cap of $302.49 million, a P/E ratio of -2.56 and a beta of 0.68.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. On average, sell-side analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its holdings in Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock worth $1,020,000 after purchasing an additional 38,321 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Astria Therapeutics by 101.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock valued at $431,000 after purchasing an additional 19,735 shares during the period. SG Americas Securities LLC raised its stake in shares of Astria Therapeutics by 51.3% in the 4th quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company's stock worth $190,000 after buying an additional 7,218 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Astria Therapeutics in the fourth quarter valued at $107,000. Finally, Rhumbline Advisers lifted its holdings in shares of Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock valued at $556,000 after buying an additional 1,381 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.